MIL •
Healthcare •
Drug Manufacturers - General •
Quote as of 09/09/2026
Company Profile
IndustryDrug Manufacturers - General
SectorHealthcare
ExchangeMIL
Market Capitalization28,537 mln
Float133 mln
Earnings Date10/30/2026
EPS
4.86
Stretched
P / E
37.30
Overvalued
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-2.51
Likely reliable
Relative Strength
33
/ 100
Underperforming
Debt / Equity
0.44
Low leverage
Business Description
Biogen is a global biopharmaceutical company focused on discovering, developing, and delivering treatments for serious neurological and rare diseases, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and several other conditions. Founded in 1978 and based in Cambridge, Massachusetts, the company markets a broad range of medicines across the United States, Europe, Asia, and beyond. Biogen also works closely with a number of partner organizations to advance new therapies in areas such as gene silencing, rare pediatric diseases, and next-generation drug delivery methods.